ArticleJournal of clinical medicine research2024
Association Between Chronic Kidney Disease Risk Categories and Abdominal Aortic Calcification: Insights From the National Health and Nutrition Examination Survey.
Article in Journal of clinical medicine research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Abdominal aortic calcification (AAC) is a critical indicator of cardiovascular risk, particularly in patients with chronic kidney disease (CKD). Traditional classification systems may underestimate the risk in those with moderate CKD. This study aimed to evaluate the association between CKD risk categories - defined by both estimated glomerular filtration rate (eGFR) and albuminuria - and the prevalence of severe AAC. Methods: This cross-sectional study analyzed data from the National Health and Nutrition Examination Survey (NHANES) 2013-2014. We included adults aged ≥ 40 years who underwent imaging for AAC assessment, excluding pregnant individuals and those without AAC scores. Survey-weighted and multivariate logistic regression was employed to assess the relationship between CKD risk categories and severe AAC, adjusting for age, hypertension, and smoking history. Subgroup analyses were conducted to explore variability across demographic and clinical subgroups. Results: We analyzed data from 3,140 participants in the NHANES, 423 (13.4%) of whom had severe AAC. The cohort was categorized into CKD risk categories 1 through 4, with the majority (76%) in stage 1. Severe AAC was more prevalent among older individuals and those with traditional cardiovascular risk factors. Initial unadjusted analyses revealed that CKD category 2 was associated with a nearly fourfold increase in severe AAC (odds ratio (OR): 3.93), while categories 3 and 4 showed 3.75-fold and over 10-fold increases, respectively (all P < 0.01). However, after adjusting for confounders, categories 2 and 4 showed higher risks of severe AAC compared to category 1, but these associations did not reach statistical significance (OR: 1.72, 95% confidence interval (CI): 0.90 - 1.86, P = 0.06 and OR: 5.70, 95% CI: 0.85 - 38.00, P = 0.07, respectively). Conclusion: Our study offers insights that may complement the current reliance on eGFR and albuminuria in risk stratification, highlighting that CKD category 2, defined by mildly reduced eGFR and albuminuria, may be a potential marker for severe AAC. Although statistical significance was narrowly missed after full adjustment, the clinical implications remain significant, advocating for more aggressive cardiovascular risk management in this population. This understanding may contribute to evolving approaches in CKD-related cardiovascular risk assessment and inform potential intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.